Our findings indicated that compared to the sh-NC group, the sh-NCL-2 and sh-NCL-3 groups (mice injected with NCL-silenced CD8+ T cells) exhibited smaller tumor volumes, suggesting the ability of NCL-silenced CD8+ T cells to inhibit tumor growth in vivo (Fig. 4H). Here, CD8A is linked to neoplasm.